At a glance
- Originator Pfizer
- Class Anti-inflammatories; Irritable bowel syndrome therapies
- Mechanism of Action Opioid delta receptor agonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- Discontinued Irritable bowel syndrome
Most Recent Events
- 04 Apr 2003 Discontinued - Preclinical for Irritable bowel syndrome in United Kingdom (unspecified route)
- 04 Apr 2003 Data presented at the 225th American Chemical Society Meeting (225th-ACS) have been added to the pharmacokinetics section
- 26 Apr 2001 Preclinical development for Irritable bowel syndrome in United Kingdom (Unknown route)